where C1 and E1 are the cost and effect in the intervention group, respectively, and C0 and E0 are the cost and effect in the control care group, respectively. Once…
!DOCTYPE html> © Springer Nature Switzerland AG 2020G. Lambru, M. Lanteri-Minet (eds.)Neuromodulation in Headache and Facial Pain ManagementHeadachehttps://doi.org/10.1007/978-3-030-14121-9_17 17. Methodological Difficulties in Clinical Trials Assessing Neuromodulation Devices in the Headache Field Mads Barloese1, 2 …
Authors Study type Number trial stimulations Number permanent implants Overall efficacy Responder (>50% pain relief) Follow-up Revision surgery/removal Major complications Johnson and Burchiel [42] Case series 11 10 n/a 70%…
!DOCTYPE html> © Springer Nature Switzerland AG 2020G. Lambru, M. Lanteri-Minet (eds.)Neuromodulation in Headache and Facial Pain ManagementHeadachehttps://doi.org/10.1007/978-3-030-14121-9_14 14. Neuromodulation in Other TACS and Other Primary Headaches Christoph J. Schankin1 and Fabio Antonaci2 (1) Department of…
Fig. 7.1 Anteroposterior (a) and lateral (b) radiographic view of the cervical spine to demonstrate the final position of the implanted lead within the posterior epidural space in a chronic…
Study No. of patients implanted (n) Follow-up: average/median months Improvement of at least 50% in intensity and/or frequency Adverse events Burns [10, 24] 14 17.5 months 5 (36%) Lead migration (29%)…
!DOCTYPE html> © Springer Nature Switzerland AG 2020G. Lambru, M. Lanteri-Minet (eds.)Neuromodulation in Headache and Facial Pain ManagementHeadachehttps://doi.org/10.1007/978-3-030-14121-9_12 12. Neuromodulation and Other Non-pharmacological Approaches in Tension-Type Headache Licia Grazzi1 , Eleonora Grignani1, Emanuela Sansone1, Miguel J. A. Láinez2 and Jésica García-Ull2…
!DOCTYPE html> © Springer Nature Switzerland AG 2020G. Lambru, M. Lanteri-Minet (eds.)Neuromodulation in Headache and Facial Pain ManagementHeadachehttps://doi.org/10.1007/978-3-030-14121-9_11 11. Neuromodulation in Migraine Michel Lanteri-Minet1 and Anne Donnet2 (1) Pain Department CHU Nice, FHU InovPain Cote…
Authors Patients Study protocol Results Gérardy et al. [14] MO (n = 10) Pilot 3-month open-label study −1.3 days reduction in monthly attack frequency Five out of ten patients satisfied Schoenen et al….
Authors Participants Study Treatment Results Antal et al. [17] MO = 12 MA = 14 Randomized sham-controlled trial Cathode over V1 No reduction was observed in attacks frequency in both groups (tDCS and sham)…
